|
1
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar
|
|
2
|
Harris AL, Nicholson S, Sainsbury JR,
Farndon J and Wright C: Epidermal growth factor receptors in breast
cancer: association with early relapse and death, poor response to
hormones and interactions with neu. J Steroid Biochem. 34:123–131.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sainsbury JR, Malcolm AJ, Appleton DR,
Farndon JR and Harris AL: Presence of epidermal growth factor
receptor as an indicator of poor prognosis in patients with breast
cancer. J Clin Pathol. 38:1225–1228. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nielsen TO, Hsu FD, Jensen K, et al:
Immunohistochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slamon DJ, Godolphin W, Jones LA, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Foster CS, Gosden CM and Ke Y: HER2/neu
expression in cancer: the pathologist as diagnostician or prophet?
Hum Pathol. 34:635–638. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rosen PP, Lesser ML, Arroyo CD, Cranor M,
Borgen P and Norton L: Immunohistochemical detection of HER2/neu in
patients with axillary lymph node negative breast carcinoma. A
study of epidemiologic risk factors, histologic features, and
prognosis. Cancer. 75:1320–1326. 1995. View Article : Google Scholar
|
|
8
|
Carlomagno C, Perrone F, Gallo C, et al:
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen
in early-stage breast cancer without axillary lymph node
metastases. J Clin Oncol. 14:2702–2708. 1996.
|
|
9
|
Gusterson BA, Gelber RD, Goldhirsch A, et
al: Prognostic importance of c-erbB-2 expression in breast cancer.
International (Ludwig) Breast Cancer Study Group. J Clin Oncol.
10:1049–1056. 1992.PubMed/NCBI
|
|
10
|
Bianco R, Melisi D, Ciardiello F and
Tortora G: Key cancer cell signal transduction pathways as
therapeutic targets. Eur J Cancer. 42:290–294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chardin P, Cussac D, Maignan S and Ducruix
A: The Grb2 adaptor. FEBS Lett. 369:47–51. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
13
|
Di Fulvio M, Henkels KM and
Gomez-Cambronero J: Short-hairpin RNA-mediated stable silencing of
Grb2 impairs cell growth and DNA synthesis. Biochem Biophys Res
Commun. 357:737–742. 2007.PubMed/NCBI
|
|
14
|
Machida K and Mayer BJ: The SH2 domain:
versatile signaling module and pharmaceutical target. Biochim
Biophys Acta. 1747:1–25. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pawson T: Protein modules and signalling
networks. Nature. 373:573–580. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mayer BJ, Jackson PK and Baltimore D: The
noncatalytic src homology region 2 segment of abl tyrosine kinase
binds to tyrosine-phosphorylated cellular proteins with high
affinity. Proc Natl Acad Sci USA. 88:627–631. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mayer BJ, Jackson PK, Van Etten RA and
Baltimore D: Point mutations in the abl SH2 domain coordinately
impair phosphotyrosine binding in vitro and transforming activity
in vivo. Mol Cell Biol. 12:609–618. 1992.PubMed/NCBI
|
|
18
|
Schwarze SR, Hruska KA and Dowdy SF:
Protein transduction: unrestricted delivery into all cells? Trends
Cell Biol. 10:290–295. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lindgren M, Hallbrink M, Prochiantz A and
Langel U: Cell-penetrating peptides. Trends Pharmacol Sci.
21:99–103. 2000. View Article : Google Scholar
|
|
20
|
Liang Y, Sun Q, Jiang S, et al:
Construction and expression of a vector containing protein
transduction domain and bcr/abl fusion gene. Zhonghua Xue Ye Xue Za
Zhi. 23:5–8. 2002.(In Chinese).
|
|
21
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sangadala S, Okada M, Liu Y, Viggeswarapu
M, Titus L and Boden SD: Engineering, cloning, and functional
characterization of recombinant LIM mineralization protein-1
containing an N-terminal HIV-derived membrane transduction domain.
Protein Expr Purif. 65:165–173. 2009. View Article : Google Scholar
|
|
23
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lung FD and Tsai JY: Grb2 SH2
domain-binding peptide analogs as potential anticancer agents.
Biopolymers. 71:132–140. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim D, Jeon C, Kim JH, et al: Cytoplasmic
transduction peptide (CTP): new approach for the delivery of
biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res.
312:1277–1288. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schwarze SR, Ho A, Vocero-Akbani A and
Dowdy SF: In vivo protein transduction: delivery of a biologically
active protein into the mouse. Science. 285:1569–1572. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tan M, Lan KH, Yao J, et al: Selective
inhibition of ErbB2-overexpressing breast cancer in vivo by a novel
TAT-based ErbB2-targeting signal transducers and activators of
transcription 3-blocking peptide. Cancer Res. 66:3764–3772. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harada H, Kizaka-Kondoh S and Hiraoka M:
Antitumor protein therapy; application of the protein transduction
domain to the development of a protein drug for cancer treatment.
Breast Cancer. 13:16–26. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sorriento D, Campanile A, Santulli G, et
al: A new synthetic protein, TAT-RH, inhibits tumor growth through
the regulation of NFkappaB activity. Mol Cancer. 8:972009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang YJS, Han H, Liu L, Sun Q, Chen R, Wu
R, Du J and Li Q: TAT PTD-BCR/ABL SH3 fusion protein induces the
apoptosis of K562 leukemic cell line. J Fourth Mil Med Univ.
23:42002.
|
|
31
|
Yin JK, Liang YM, He XL, et al: Fusion
protein containing SH3 domain of c-Abl induces hepatocarcinoma
cells to apoptosis. Hepatol Res. 37:454–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ogura K, Shiga T, Yokochi M, Yuzawa S,
Burke TR Jr and Inagaki F: Solution structure of the Grb2 SH2
domain complexed with a high-affinity inhibitor. J Biomol NMR.
42:197–207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dierck K, Machida K, Mayer BJ and Nollau
P: Profiling the tyrosine phosphorylation state using SH2 domains.
Methods Mol Biol. 527:131–155. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jiang X, Huang F, Marusyk A and Sorkin A:
Grb2 regulates internalization of EGF receptors through
clathrin-coated pits. Mol Biol Cell. 14:858–870. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamazaki T, Zaal K, Hailey D, Presley J,
Lippincott-Schwartz J and Samelson LE: Role of Grb2 in
EGF-stimulated EGFR internalization. J Cell Sci. 115:1791–1802.
2002.PubMed/NCBI
|
|
36
|
Burke P, Schooler K and Wiley HS:
Regulation of epidermal growth factor receptor signaling by
endocytosis and intracellular trafficking. Mol Biol Cell.
12:1897–1910. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schulze WX, Deng L and Mann M:
Phosphotyrosine inter-actome of the ErbB-receptor kinase family.
Mol Syst Biol. 1:2005.0008. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Seiden-Long I, Navab R, Shih W, et al:
Gab1 but not Grb2 mediates tumor progression in Met overexpressing
colorectal cancer cells. Carcinogenesis. 29:647–655.
2008.PubMed/NCBI
|
